KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Total Debt: 2017-2025

Historic Total Debt for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to $2.6 billion.

  • Amneal Pharmaceuticals' Total Debt rose 7.49% to $2.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 billion, marking a year-over-year increase of 7.49%. This contributed to the annual value of $2.4 billion for FY2024, which is 6.98% down from last year.
  • According to the latest figures from Q3 2025, Amneal Pharmaceuticals' Total Debt is $2.6 billion, which was up 5.64% from $2.4 billion recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Total Debt ranged from a high of $2.8 billion in Q1 2021 and a low of $2.4 billion during Q4 2024.
  • Its 3-year average for Total Debt is $2.5 billion, with a median of $2.6 billion in 2024.
  • In the last 5 years, Amneal Pharmaceuticals' Total Debt fell by 10.22% in 2021 and then rose by 7.49% in 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Total Debt (Quarterly) stood at $2.7 billion in 2021, then dropped by 2.78% to $2.7 billion in 2022, then fell by 3.28% to $2.6 billion in 2023, then fell by 6.98% to $2.4 billion in 2024, then climbed by 7.49% to $2.6 billion in 2025.
  • Its Total Debt stands at $2.6 billion for Q3 2025, versus $2.4 billion for Q2 2025 and $2.4 billion for Q1 2025.